Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New sedative studied in patients with low protein levels

NCT ID NCT06425757

Knowledge-focused Sponsor: Xie Kangjie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the sedative drug ciprofol is processed in the body of people with moderate to severe low blood protein (hypoproteinemia). Researchers measured drug levels in the blood after a single injection in 36 patients. The goal was to understand dosing and timing, not to treat the condition itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

36 people

The number who actually took part.

Started

Apr 2024

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with moderate to severe hypoproteinemia (albumin \< 30g/L, protein detection time uniformly within three days before surgery） * Weight greater than 45kg, BMI20-24 * The ASA rating is Class I or Class II Exclusion Criteria: * Severe liver dysfunction * Severe renal dysfunction * Patients with ASA grade III and above * Known allergy to eggs, soy products, opioids and their relief drugs, propofol * Emergency surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ciprofol are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

channelopathy-associated congenital insensitivity to pain, autosomal recessive Hypoproteinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ciprofol Hypoproteinemia Pharmacokinetics

Contacts and locations

Locations

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.